Loading...
Loading...
NTRA| Name | Value |
|---|---|
| Revenues | 439.8M |
| Cost of Revenue | 168.0M |
| Gross Profit | 271.7M |
| Operating Expense | 311.1M |
| Operating I/L | -39.3M |
| Other Income/Expense | 8.5M |
| Interest Income | 11.6M |
| Pretax | -30.9M |
| Income Tax Expense | 0.7M |
| Net Income/Loss | -31.6M |
Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services globally. The company's revenue is generated through a range of products including non-invasive prenatal tests, single-gene mutation screening, carrier screening for genetic diseases, miscarriage test products, non-invasive paternity testing, cloud-based software for laboratory customers, circulating tumor DNA technology, and organ transplant rejection assessment. Natera sells its products through a direct sales force and a network of approximately 100 laboratory and distribution partners. Additionally, the company has partnership agreements with BGI Genomics Co., Ltd. and Foundation Medicine, Inc. for the development and commercialization of genetic testing assays and personalized circulating tumor DNA monitoring assays.
